WO2005074658A3 - Carbonyl iron pharmaceutical dosage forms for the treatment of iron-deficiency anemia - Google Patents

Carbonyl iron pharmaceutical dosage forms for the treatment of iron-deficiency anemia Download PDF

Info

Publication number
WO2005074658A3
WO2005074658A3 PCT/US2005/003922 US2005003922W WO2005074658A3 WO 2005074658 A3 WO2005074658 A3 WO 2005074658A3 US 2005003922 W US2005003922 W US 2005003922W WO 2005074658 A3 WO2005074658 A3 WO 2005074658A3
Authority
WO
WIPO (PCT)
Prior art keywords
iron
treatment
deficiency anemia
dosage forms
pharmaceutical dosage
Prior art date
Application number
PCT/US2005/003922
Other languages
French (fr)
Other versions
WO2005074658A2 (en
Inventor
Anandi Krishnan
M E Kannan
Preethi B Rao
Original Assignee
Glenmark Pharmaceuticals Inc U
Glenmark Pharmaceuticals Ltd
Anandi Krishnan
M E Kannan
Preethi B Rao
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/772,745 external-priority patent/US20050170014A1/en
Application filed by Glenmark Pharmaceuticals Inc U, Glenmark Pharmaceuticals Ltd, Anandi Krishnan, M E Kannan, Preethi B Rao filed Critical Glenmark Pharmaceuticals Inc U
Publication of WO2005074658A2 publication Critical patent/WO2005074658A2/en
Publication of WO2005074658A3 publication Critical patent/WO2005074658A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to a pharmaceutical composition including an active pharmaceutical ingredient for the treatment of iron-deficiency anemia and related disorders. The active pharmaceutical ingredient is preferably carbonyl iron. The formulation of the pharmaceutical composition of the present invention ensures enhanced absorption of iron in its ferrous form. Also contemplated by the present invention are the methods of making the pharmaceutical composition.
PCT/US2005/003922 2004-01-30 2005-01-31 Carbonyl iron pharmaceutical dosage forms for the treatment of iron-deficiency anemia WO2005074658A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN106MU2004 2004-01-30
IN106/MUM/2004 2004-01-30
US10/772,745 US20050170014A1 (en) 2004-01-30 2004-02-04 Carbonyl iron pharmaceutical dosage forms for the treatment of iron-deficiency anemia
US10/772,745 2004-02-04

Publications (2)

Publication Number Publication Date
WO2005074658A2 WO2005074658A2 (en) 2005-08-18
WO2005074658A3 true WO2005074658A3 (en) 2007-06-07

Family

ID=34839948

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/003922 WO2005074658A2 (en) 2004-01-30 2005-01-31 Carbonyl iron pharmaceutical dosage forms for the treatment of iron-deficiency anemia

Country Status (1)

Country Link
WO (1) WO2005074658A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6368625B1 (en) * 1998-08-12 2002-04-09 Cima Labs Inc. Orally disintegrable tablet forming a viscous slurry
US6521247B1 (en) * 1999-08-13 2003-02-18 Warner Chilcott Laboratories Ireland Limited Dual iron containing nutritional supplement

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6368625B1 (en) * 1998-08-12 2002-04-09 Cima Labs Inc. Orally disintegrable tablet forming a viscous slurry
US6521247B1 (en) * 1999-08-13 2003-02-18 Warner Chilcott Laboratories Ireland Limited Dual iron containing nutritional supplement

Also Published As

Publication number Publication date
WO2005074658A2 (en) 2005-08-18

Similar Documents

Publication Publication Date Title
MY143795A (en) Tetrahydropyridoindole derivatives
WO2007127158A3 (en) Modification of percutaneous absorption of topically active materials
WO2005041925A3 (en) Compositions and dosage forms for enhanced absorption
WO2006014673A3 (en) Insulin-oligomer conjugates, formulations and uses thereof
WO2005097075A3 (en) Tamper resistant dosage form comprising an adsorbent and an adverse agent
WO2004078116A3 (en) P38 inhibitors and methods of use thereof
WO2005092392A3 (en) Conjugated psychotropic drugs and uses thereof
BRPI0513455A (en) flavor masking formulation comprising the drug in a delayed dissolution form and / or cyclodextrin in an improved dissolution form
EA017764B8 (en) Pharmaceutical composition, method for preparation thereof and method for treating antiviral diseases using same
WO2006096439A3 (en) Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
WO2006096434A3 (en) Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
EP2526933A3 (en) Inhibitors of bruton's tyrosine kinase
WO2007064968A3 (en) Stable pharmaceutical compositions of 5,10 methylenetetrahydrofolate
WO2006074265A3 (en) Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
WO2005092009A3 (en) Acetylcholinesterase inhibitors and n-methyl-d-aspartate antagonists useful in the treatment of cognitive disorders
WO2004045593A3 (en) Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
TNSN07193A1 (en) Pharmaceutical compositions comprising a camptothecin derivate
WO2007044180A3 (en) Improved toleration iron supplement compositions
CA2494473A1 (en) Stabilized protein compositions for topical administration and methods of making same
CY1112637T1 (en) ACTIVITIES FOR PREVENTING AND TREATING US DISEASES CONTAINING A PYRAZOLOPYRIMIDIN PRODUCT
WO2005082413A3 (en) Ciclesonide and glycopyrronium combination
MY153713A (en) A pharmaceutical composition comprising 3, 4-dihydro-3-methyl-4-oxoimidazo [5,1-d]-1,2,3,5-tetrazine-8-carboxylate
WO2005118584A3 (en) Saframycin analogs as therapeutic agents in the treatment of cancer
WO2006015970A3 (en) Medicaments for the prevention or treatment of alveolar pneumonia comprising an anticholinergic
WO2005123113A3 (en) Interferon compositions and methods of use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase